

Global Congress on Public Health 2025

July 23-24, 2025 | Paris, France



Yannan Chen

Chongqing General Hospital, Chongqing, China

Clinical Efficacy of Modified Gancao Ganjiang Decoction Combined with Vitamin B₁₂ on Recurrent Oral Ulcer

Objective

To explore the clinical efficacy of modified Gancao Ganjiang Decoction combined with Vitamin B₁₂ (VB₁₂) on recurrent oral ulceration (ROU).

Methods

A total of 124 ROU patients admitted to Chongqing General Hospital from August 2016 to August 2018 were selected as the research objects and were divided into an observation group and a control group, with 62 cases in each group, according to random number table. The control group was administered orally with VB₁₂, while the observation group was treated with Jiawei Gancao Ganjiang Decoction plus VB₁₂. All patients were treated for 14 days. The clinical efficacy and safety between the 2 groups were compared.

Results

The overall effective rate of the observation group reached 96.8% (60/62), much higher than 85.5% (53/62) of the control group ($P < 0.05$). Compared with those before treatment, the pain index, ulcer area and average ulcer period were significantly improved in the 2 groups after treatment ($P < 0.05$), peripheral blood CD3⁺, CD4⁺ levels, CD4⁺/CD8⁺ ratio, and the number of streptococcus and veillonella in saliva increased significantly ($P < 0.05$), peripheral blood CD8⁺ level decreased significantly ($P < 0.05$); and the observation group improved more significantly than the control group in indicators ($P < 0.05$). There were no obvious side effects in both groups. Follow-up for 6 months, the recurrence rate of the observation group was 11.3% (7/62) significantly lower than that of the control group [25.8% (16/62)] ($P < 0.05$).

Conclusion

The overall curative effect of Jiawei Gancaoganjiang Decoction combined with VB₁₂ in the treatment of ROU is definite and may be related to its significantly correction of the immune imbalance of peripheral blood T lymphocyte subsets and maintaining the homeostasis of the oral microenvironment.

Key words: Recurrent oral ulceration, Modified Gancao Ganjiang Decoction, Vitamin B₁₂, T-lymphocyte subsets, Oral microenvironment, Recurrence risk, Mechanism of action, Safety

Global Congress on Public Health 2025

July 23-24, 2025 | Paris, France

表1 2组患者临床疗效比较

组别	显效(例)	有效(例)	无效(例)	治疗有效率(%)
观察组(n=62)	39	21	2	96.8*
对照组(n=62)	30	23	9	85.5

注:与对照组比较,*P<0.05

表2 2组患者疼痛指数、溃疡面积、平均溃疡期比较($\bar{x} \pm s$)

组别	疼痛指数(分)	溃疡面积(mm ²)	平均溃疡期(d)
观察组(n=62)			
治疗前	7.14±1.29	14.73±3.25	7.35±1.69
治疗后	0.71±0.15* [△]	3.07±0.60* [△]	1.56±0.44* [△]
对照组(n=62)			
治疗前	6.83±1.08	15.64±3.52	7.02±1.78
治疗后	1.58±0.37*	5.21±1.08*	2.74±0.53*

注:与治疗前比较,*P<0.05;与对照组治疗后比较,[△]P<0.05

表3 2组患者T淋巴细胞亚群水平比较($\bar{x} \pm s$)

组别	CD3 ⁺ (%)	CD4 ⁺ (%)	CD8 ⁺ (%)	CD4 ⁺ /CD8 ⁺
观察组(n=62)				
治疗前	62.57±9.42	28.65±5.98	30.73±6.09	0.95±0.19
治疗后	69.50±6.31* [△]	34.52±4.87* [△]	25.94±4.58* [△]	1.30±0.21* [△]
对照组(n=62)				
治疗前	63.85±8.79	29.74±6.11	29.84±6.30	0.98±0.17
治疗后	66.77±7.46*	32.19±5.36*	27.72±5.17*	1.15±0.22*

注:与治疗前比较,*P<0.05;与对照组治疗后比较,[△]P<0.05

表4 2组患者口腔微环境参数比较($\bar{x} \pm s$, lg copies/mL)

组别	链球菌	韦荣氏菌
观察组(n=62)		
治疗前	7.13±0.94	8.16±0.92
治疗后	7.84±0.72* [△]	8.92±0.72* [△]
对照组(n=62)		
治疗前	6.89±1.05	8.25±1.08
治疗后	7.47±0.80*	8.61±0.85*

注:与治疗前比较,*P<0.05;与对照组治疗后比较,[△]P<0.05